Arax Advisory Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Arax Advisory Partners's RXRX Position: Q2 2026 in Review

Arax Advisory Partners increased its Recursion Pharmaceuticals (RXRX) stake by 863% in Q2 2026, buying an estimated $55K and bringing the position to 18,444 shares worth $67.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Arax Advisory Partners first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

• Arax Advisory Partners held 18,444 shares of Recursion Pharmaceuticals worth $67.7K as of Q2 2026.
• Arax Advisory Partners bought 16,529 Recursion Pharmaceuticals shares in Q2 2026, an estimated $55K.
• Recursion Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3025 holding.
• Arax Advisory Partners first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
• 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.